Classification analysis of P-glycoprotein substrate specificity

被引:205
作者
Didziapetris, R
Japertas, P
Avdeef, A
Petrauskas, A
机构
[1] Pharma Algorithms Inc, LT-2001 Vilnius, Lithuania
[2] Vilnius Univ, Fac Chem, LT-2006 Vilnius, Lithuania
[3] pION Inc, Woburn, MA 01801 USA
关键词
P-glycoprotein; blood-brain barrier; CNS; ADME predictions; fuzzy specificity; property-based design;
D O I
10.1080/10611860310001648248
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Prediction of P-glycoprotein substrate specificity (S-PGP) can be viewed as a constituent part of a compound's "pharmaceutical profiling" in drug design. This task is difficult to achieve due to several factors that raised many contradictory opinions: (i) the disparity between the S-PGP values obtained in different assays, (ii) the confusion between Pgp substrates and inhibitors, (iii) the confusion between lipophilicity and amphiphilicity of Pgp substrates, and (iv) the dilemma of describing class-specific relationships when Pgp has no binding sites of high ligand specificity. In this work, we compiled S-PGP data for 1000 compounds. All data were represented in a binary format, assigning S-PGP =1 for substrates and S-PGP =0 for non-substrates. Each value was ranked according to the reliability of experimental assay. Two data sets were considered. Set 1 included 220 compounds with S-PGP from polarized transport across MDR1 transfected cell monolayers. Set 2 included the entire list of 1000 compounds, with S-PGP values of generally lower reliability. Both sets were analysed using a stepwise classification structure-activity relationship (C-SAR) method, leading to derivation of simple rules for crude estimation of S-PGP values. The obtained rules are based on the following factors: (i) compound's size expressed through molar weight or volume, (ii) H-accepting given by the Abraham's beta (that can be crudely approximated by the sum of O and N atoms), and (iii) ionization given by the acid and base pK(a) values. Very roughly, S-PGP can be estimated by the "rule of fours". Compounds with (N+O)greater than or equal to8, MW>400 and acid pK(a) > 4 are likely to be Pgp substrates, whereas compounds with (N+O)less than or equal to4, MW<400 and base pK(a) <8 are likely to be non-substrates. The obtained results support the view that Pgp functioning can be compared to a complex "mini-pharmacokinetic" system with fuzzy specificity. This system can be described by a probabilistic version of Abraham's solvation equation, suggesting a certain similarity between Pgp transport and chromatographic retention. The chromatographic model does not work in the case of "marginal" compounds with properties close to the "global" physicochemical cut-offs. In the latter case various class-specific rules must be considered. These can be associated with the "amphiphilicity" and "biological similarity" of compounds. The definition of class-specific effects entails construction of the knowledge base that can be very useful in ADME profiling of new drugs.
引用
收藏
页码:391 / 406
页数:16
相关论文
共 171 条
[1]   Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in man [J].
Abel, S ;
Beaumont, KC ;
Crespi, CL ;
Eve, MD ;
Fox, L ;
Hyland, R ;
Jones, BC ;
Muirhead, GJ ;
Smith, DA ;
Venn, RF ;
Walker, DK .
XENOBIOTICA, 2001, 31 (8-9) :665-676
[3]   HYDROGEN-BONDING .38. EFFECT OF SOLUTE STRUCTURE AND MOBILE-PHASE COMPOSITION ON REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC CAPACITY FACTORS [J].
ABRAHAM, MH ;
ROSES, M .
JOURNAL OF PHYSICAL ORGANIC CHEMISTRY, 1994, 7 (12) :672-684
[4]   Solute effects on reversed-phase thin-layer chromatography A linear free energy relationship analysis [J].
Abraham, MH ;
Poole, CF ;
Poole, SK .
JOURNAL OF CHROMATOGRAPHY A, 1996, 749 (1-2) :201-209
[5]  
Abraham MH, 1999, PESTIC SCI, V55, P78, DOI 10.1002/(SICI)1096-9063(199901)55:1<78::AID-PS853>3.0.CO
[6]  
2-7
[7]   Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein [J].
Adachi, Y ;
Suzuki, H ;
Sugiyama, Y .
PHARMACEUTICAL RESEARCH, 2001, 18 (12) :1660-1668
[8]  
Aksentijevich I, 1996, CLIN CANCER RES, V2, P973
[9]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[10]   Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein [J].
Ayesh, S ;
Shao, YM ;
Stein, WD .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1996, 1316 (01) :8-18